WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
about
Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screeningDegrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3βThe constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617.A chemical screen identifies small molecules that regulate hepcidin expression.Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivoUnderstanding the biology of CRLF2-overexpressing acute lymphoblastic leukemiaMYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmPolycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.Recent developments on JAK2 inhibitors: a patent review.Interleukins in glioblastoma pathophysiology: implications for therapy.Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis.Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130.AG490: an inhibitor of hepcidin expression in vivo.Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.Eriodictyol Attenuates Myocardial Ischemia-Reperfusion Injury through the Activation of JAK2.Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice.
P2860
Q30416775-A1AD3EBF-2FA7-4747-A722-ADA6AD6C31FBQ33586552-6D700A09-0F66-4F87-9506-BCEC0013C774Q33616659-F06E0A61-56ED-4E62-98F1-D8FBCDDA2E5BQ33832937-F24C8D70-21B2-476F-825A-020D50D6DB2BQ33903747-CCE7954B-6F83-4D6F-85F9-C03857D266BDQ34075662-920552C2-72B9-4B97-8E8C-373B93D30785Q34316190-B69F8790-20C9-4579-B587-2B05AB063B12Q34345426-8CD53DD5-F7E1-4AC6-AA6B-9FCD29655A7CQ35164307-2B5542C7-0635-4793-A571-E7EF6DA78371Q35500533-F319CE40-2633-489D-951D-DEA90B791DAEQ35685245-CB9EEA1F-42D7-4ADB-AE30-3D688795775FQ36612569-7F5E8614-B6B1-4AA1-924B-6DCD16FA568CQ37441169-EC3F47F7-EAF6-493D-99F5-5EFE79A4E9F0Q37703253-DB4DA54E-1149-4F6C-B86B-E871010F8897Q38051761-2EA646BC-BF4E-4952-A31A-00F03A127396Q39024059-2D138353-8F88-4555-A1B1-47AF171E1DD8Q39031307-9A79C534-9C42-4C04-BD23-6212A37D26EEQ39554914-6A3EE056-E0A9-44AE-A4AE-2D72A7566188Q39643717-A7430605-03FB-4A07-9BA4-5B887D8F126EQ39717742-8CB45A08-BC27-4ECD-B668-5C0F8EBA27D6Q42591199-E700ABAD-267B-4DBC-A3DF-AC5B8D533DB4Q43010168-4EA1ABEF-83B1-4F70-A792-9860B90DE28CQ46040082-82609F86-BDD6-4820-AF0F-B0F7239D63DAQ49345473-B07DDCB4-AA70-4F4A-83FE-9627B3013561Q53279536-D8F312FB-5FE7-4E81-91AE-9CFCD4FB8D69
P2860
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@ast
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@en
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@nl
type
label
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@ast
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@en
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@nl
prefLabel
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@ast
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@en
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@nl
P2093
P50
P1476
WP1066, a novel JAK2 inhibitor ...... rying the JAK2 V617F mutation.
@en
P2093
Alfonso Quintás-Cardama
David Harris
Francis J Giles
Taghi Manshouri
Waldemar Priebe
P304
P356
10.1158/1078-0432.CCR-07-0524
P407
P577
2008-02-01T00:00:00Z